tbuckley/cabot-search huggingface dataset:
Just One More Hug
Authors: Jayshil J. Patel
Journal: Annals of Internal Medicine (2015)

On Being a Doctor1 December 2015Just One More HugJayshil J. Patel, MDJayshil J. Patel, MDFrom Medical College of Wisconsin, Milwaukee, Wisconsin.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-1590 Audio Reading - “Just One More Hug” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Just One More Hug" by J.J. Patel. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail It was nearly 8:00 p.m. on a Monday, well past my 3-year-old daughter's bedtime. Her usual routine of eating dinner, brushing her teeth, bathing, and reading a book was considerably delayed because of my tardiness picking her up from daycare. She was avoiding sleep at all costs, repeatedly asking me for “just one more hug.” During the fourth hug, when she wrapped her arms snugly around my neck, I found myself becoming impatient, knowing I still had to write notes on 20 ICU patients on my home laptop.Earlier that day, I had picked up a busy ICU service. During ... Author, Article, and Disclosure InformationAffiliations: From Medical College of Wisconsin, Milwaukee, Wisconsin.Corresponding Author: Jayshil J. Patel, MD, 9200 West Wisconsin Avenue, Suite E-5200, Pulmonary & Critical Care, Milwaukee, WI 53226; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Just One More Hug” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Just One More Hug" by J.J. Patel. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 1 December 2015Volume 163, Issue 11Page: 882KeywordsComputersEmotionsHeartIntensive care unitsMuscular dystrophiesMyocardial infarctionShinglesSleepThoraxWalking ePublished: 1 December 2015 Issue Published: 1 December 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Long-term Realism and Cost-effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide
Authors: Freddie Bray, Ahmedin Jemal, Lindsey A. Torre, David Forman, Paolo Vineis
Journal: JNCI Journal of the National Cancer Institute (2015)

The global figure of 14 million new cancer cases in 2012 is projected to rise to almost 22 million by 2030, with the burden in low- and middle-income countries (LMICs) shifting from 59% to 65% of all cancer cases worldwide over this time. While the overheads of cancer care are set to rapidly increase in all countries worldwide irrespective of income, the limited resources to treat and manage the growing number of cancer patients in LMICs threaten national economic development. Current data collated in the recent second edition of The Cancer Atlas by the American Cancer Society and International Agency for Research on Cancer show that a substantial proportion of cancers are preventable and that prevention is cost-effective. Therefore, cancer control strategies within countries must prioritize primary and secondary prevention, alongside cancer management and palliative care and integrate these measures into existing health care plans. There are many examples of the effectiveness of prevention in terms of declining cancer rates and major risk factors, including an 80% decrease in liver cancer incidence rates among children and young adults following universal infant hepatitis B vaccination in Taiwan and a 46% reduction in smoking prevalence in Brazil after the implementation of a more aggressive tobacco control program beginning in 1989. Prevention can bring rich dividends in net savings but actions must be promoted and implemented. The successful approaches to combatting certain infectious diseases provide a model for implementing cancer prevention, particularly in LMICs, via the utilization of existing infrastructures for multiple purposes.
Data Needs in Oncology: “Making Sense of The Big Data Soup”
Authors: Jessica K. DeMartino, Jonathan K. Larsen
Journal: Journal of the National Comprehensive Cancer Network (2013)

Rising health care costs and continued concerns about safety, efficacy, and quality have resulted in the demand for more data and evidence by payors, regulators, providers, and patients alike. Stakeholders with different objectives for the use of data are driving the need for more and “better” data. It is important for organizations to not only understand how to handle and collect data but also translate it into actionable information that can help transform health care delivery. Appropriate use of data can lead to reduced health care costs and increased value to all stakeholders. In June 2012, NCCN assembled a work group composed of thought leaders from NCCN Member Institutions and other organizations to identify and examine the challenges of data generation, collection, and application for clinical, regulatory, and coverage decision-making. The NCCN Data Needs Work Group identified 4 main areas for consideration: data sources, patient-derived data, payor-collected data, and regulatory policy toward data generation and use.
Elevated Immunofluorescence Antibody Titers to Several Herpesviruses in Burkitt's Lymphoma Patients: Are High Titers Unique? 2
Authors: Frans Hilgers, Andrew G. Dean, Guy de-Thé
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Elevated Immunofluorescence Antibody Titers to Several Herpesviruses in Burkitt's Lymphoma Patients: Are High Titers Unique? Get access Frans Hilgers, Frans Hilgers Search for other works by this author on: Oxford Academic PubMed Google Scholar Andrew G. Dean, Andrew G. Dean Search for other works by this author on: Oxford Academic PubMed Google Scholar Guy de-Thé Guy de-Thé Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 1, January 1975, Pages 49–51, https://doi.org/10.1093/jnci/54.1.49 Published: 01 January 1975 Article history Received: 22 July 1974 Accepted: 06 September 1974 Published: 01 January 1975
Silencing of duplicate genes: a null allele polymorphism for lactate dehydrogenase in brown trout (Salmo trutta).
Authors: F W Allendorf, G Ståhl, N Ryman
Journal: Molecular Biology and Evolution (1984)

A previously described isozyme polymorphism at one of two skeletal muscle LdhA loci in brown trout is due to a null allele, Ldh1(n), producing no detectable catalytic activity. Homozygotes for this allele have approximately only 56% of the LDH activity in skeletal muscle relative to homozygotes for the active allele. The remaining activity results from enzyme subunits produced by other LDH loci. The Ldh1(n) allele is common and widespread throughout brown trout populations in Sweden and is also found in populations from Ireland. The persistence of duplicate gene expression for the LdhA loci in almost all salmonid species is best explained by natural selection against individuals containing null alleles. However, there is no indication of natural selection against brown trout with the Ldh1(n) allele: We suggest that the selection against individuals containing null alleles that is apparently responsible for the persistence of duplicate LdhA loci in salmonids occurs only under certain environmental conditions.
Glomerular Aging and Focal Global Glomerulosclerosis
Authors: Jeffrey B. Hodgin, Markus Bitzer, Larysa Wickman, Farsad Afshinnia, Su Q Wang, Christopher O’Connor, Yan Yang, Chrysta Meadowbrooke, Mahboob Chowdhury, Masao Kikuchi, Jocelyn E. Wiggins, Roger C. Wiggins
Journal: Journal of the American Society of Nephrology (2015)

Kidney aging is associated with an increasing proportion of globally scarred glomeruli, decreasing renal function, and exponentially increasing ESRD prevalence. In model systems, podocyte depletion causes glomerulosclerosis, suggesting age-associated glomerulosclerosis could be caused by a similar mechanism. We measured podocyte number, size, density, and glomerular volume in 89 normal kidney samples from living and deceased kidney donors and normal poles of nephrectomies. Podocyte nuclear density decreased with age due to a combination of decreased podocyte number per glomerulus and increased glomerular volume. Compensatory podocyte cell hypertrophy prevented a change in the proportion of tuft volume occupied by podocytes. Young kidneys had high podocyte reserve (podocyte density >300 per 106µm3), but by 70–80 years of age, average podocyte nuclear density decreased to, <100 per 106µm3, with corresponding podocyte hypertrophy. In older age podocyte detachment rate (urine podocin mRNA-to-creatinine ratio) was higher than at younger ages and podocytes were stressed (increased urine podocin-to-nephrin mRNA ratio). Moreover, in older kidneys, proteinaceous material accumulated in the Bowman space of glomeruli with low podocyte density. In a subset of these glomeruli, mass podocyte detachment events occurred in association with podocytes becoming binucleate (mitotic podocyte catastrophe) and subsequent wrinkling of glomerular capillaries, tuft collapse, and periglomerular fibrosis. In kidneys of young patients with underlying glomerular diseases similar pathologic events were identified in association with focal global glomerulosclerosis. Podocyte density reduction with age may therefore directly lead to focal global glomerulosclerosis, and all progressive glomerular diseases can be considered superimposed accelerators of this underlying process.
Lifelong penicillin unproved in trials..
Authors: M Makris, M Greaves, D A Winfield, F E Preston, J S Lilleyman
Journal: BMJ (1994)

EDITOR, - The Editor's Choice in the issue of 27 November, which mentions the two articles and editorial on sepsis after splenectomy,*RF 1-3* highlights the possible medicolegal consequences if the advice given is not followed. We are concerned about the dogmatic nature of some of the recommendations.

We accept that after splenectomy there is a lifelong small risk of serious sepsis. We also accept the value of pneumococcal vaccine, support the recommendation that all patients who have had a splenectomy should be vaccinated, and are persuaded that revaccination every …
Letter by Lin et al Regarding Article, “Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.”
Authors: Gen-Min Lin, Yuan Hung, Yi-Hwei Li
Journal: Circulation (2015)

We read with interest the work by Abdul-Rahim et al, 1 which reported that body mass index is inversely associated with incident ischemic stroke in chronic heart failure (HF) patients without atrial fibrillation (AF).The authors reasoned their finding by the obesity paradox phenomenon which has been well recognized in HF patients in previous studies. 2However, to our best knowledge, the obesity paradox was mainly described for mortality in patients with established cardiovascular disease such as HF or AF, but as for ischemic stroke, their finding was novel.According to a few available studies, overweight or obesity, defined by body mass index ≥25 kg/m 2 , was associated with higher risk of ischemic stroke or thromboembolism events as compared with normal weight (18.5-25 kg/m 2 ) in patients with AF. 3,4 Therefore, whether the effect of HF may alter the positive association between body mass index and ischemic stroke in patients with AF needs further investigation.In addition, the obesity paradox for ischemic stroke was absent in patients without AF in the multivariable model additionally adjusted for plasma N-terminal pro B-type natriuretic peptide levels.This finding could be explained partially by that when clinical trials enrolled different stage of HF patients, lean patients may stand for in an advanced stage of HF after exhausting total body fat gradually from initial obesity to cardiac cachexia. 5n advanced HF stage, intracardiac blood clot would be produced easily in a hypercoagulant status which leads to a higher risk of ischemic stroke as well.In conclusion, the association between body mass index and incident ischemic stroke in the remaining 3531 patients with AF in the present study is worth investigation.Moreover, whether lean patients have experienced longer periods of HF and had more severe symptoms than obese counterparts among patients without AF at the entry of present study needs to be clarified.
Medical Contacts Urged with People's Republic of China
Authors: E G Dimond
Journal: New England Journal of Medicine (1979)

Normalization of relations between the Peoples Republic of China and the United States should provide opportunities for scientific and medical information exchange and collaborative research.  US medical organizations are urged to establish communication channels with the Chinese.  Initial inquiry and contacts can be made through the following: Dr. Wu Chieh-ping MD vice president Chinese Academy of Medical Science in Peking Peoples Republic of China;  Chinese Medical Association 42 Tung Ssu Hsi Ta Chieh Peking Peoples Republic (direct letters to Chen Chih-ming MD vice president and secretary-general or to Tu Pao-chung MD deputy secretary-general Chinese Medical Association;  Mr. Hu Nansheng Embassy Peoples Republic of China 2300 Connecticut Avenue Washington D.C. 20008;  T. O. Cheng MD U.S.-China Physicians Friendship Association George Washington University Medical Center 2150 Pennsylvania Avenue NW Washington D.C. 20037.
International and Interdisciplinary Identification of Health Care Transition Outcomes
Authors: Cynthia Fair, Jessica Cuttance, Niraj Sharma, Gary Maslow, Lori Wiener, Cecily Betz, Jerlym Porter, Suzanne McLaughlin, Jordan Gilleland-Marchak, Amy Renwick, Diana Naranjo, Sophia Jan, Karina Javalkar, Maria Ferris
Journal: JAMA Pediatrics (2015)

<h3>Importance</h3> There is a lack of agreement on what constitutes successful outcomes for the process of health care transition (HCT) among adolescent and young adults with special health care needs. <h3>Objective</h3> To present HCT outcomes identified by a Delphi process with an interdisciplinary group of participants. <h3>Design, Setting, and Participants</h3> A Delphi method involving 3 stages was deployed to refine a list of HCT outcomes. This 18-month study (from January 5, 2013, of stage 1 to July 3, 2014, of stage 3) included an initial literature search, expert interviews, and then 2 waves of a web-based survey. On this survey, 93 participants from outpatient, community-based, and primary care clinics rated the importance of the top HCT outcomes identified by the Delphi process. Analyses were performed from July 5, 2014, to December 5, 2014. <h3>Exposures</h3> Health care transition outcomes of adolescents and young adults with special health care needs. <h3>Main Outcomes and Measures</h3> Importance ratings of identified HCT outcomes rated on a Likert scale from 1 (not important) to 9 (very important). <h3>Results</h3> The 2 waves of surveys included 117 and 93 participants as the list of outcomes was refined. Transition outcomes were refined by the 3 waves of the Delphi process, with quality of life being the highest-rated outcome with broad agreement. The 10 final outcomes identified included individual outcomes (quality of life, understanding the characteristics of conditions and complications, knowledge of medication, self-management, adherence to medication, and understanding health insurance), health services outcomes (attending medical appointments, having a medical home, and avoidance of unnecessary hospitalization), and a social outcome (having a social network). Participants indicated that different outcomes were likely needed for individuals with cognitive disabilities. <h3>Conclusions and Relevance</h3> Quality of life is an important construct relevant to HCT. Future research should identify valid measures associated with each outcome and further explore the role that quality of life plays in the HCT process. Achieving consensus is a critical step toward the development of reliable and objective comparisons of HCT outcomes across clinical conditions and care delivery locations.
Melanocyte antigen triggers autoimmunity in human psoriasis
Authors: Akiko Arakawa, Katherina Siewert, Julia Stöhr, Petra Besgen, Song-Min Kim, Geraldine Rühl, Jens Nickel, Sigrid Vollmer, Peter Thomas, Stefan Krebs, Stefan Pinkert, Michael Spannagl, Kathrin Held, Claudia Kammerbauer, Robert Besch, Klaus Dornmair, Jörg C. Prinz
Journal: The Journal of Experimental Medicine (2015)

Psoriasis vulgaris is a common T cell–mediated inflammatory skin disease with a suspected autoimmune pathogenesis. The human leukocyte antigen (HLA) class I allele, HLA-C*06:02, is the main psoriasis risk gene. Epidermal CD8+ T cells are essential for psoriasis development. Functional implications of HLA-C*06:02 and mechanisms of lesional T cell activation in psoriasis, however, remained elusive. Here we identify melanocytes as skin-specific target cells of an HLA-C*06:02–restricted psoriatic T cell response. We found that a Vα3S1/Vβ13S1 T cell receptor (TCR), which we had reconstituted from an epidermal CD8+ T cell clone of an HLA-C*06:02–positive psoriasis patient specifically recognizes HLA-C*06:02–positive melanocytes. Through peptide library screening, we identified ADAMTS-like protein 5 (ADAMTSL5) as an HLA-C*06:02–presented melanocytic autoantigen of the Vα3S1/Vβ13S1 TCR. Consistent with the Vα3S1/Vβ13S1-TCR reactivity, we observed numerous CD8+ T cells in psoriasis lesions attacking melanocytes, the only epidermal cells expressing ADAMTSL5. Furthermore, ADAMTSL5 stimulation induced the psoriasis signature cytokine, IL-17A, in CD8+ T cells from psoriasis patients only, supporting a role as psoriatic autoantigen. This unbiased analysis of a TCR obtained directly from tissue-infiltrating CD8+ T cells reveals that in psoriasis HLA-C*06:02 directs an autoimmune response against melanocytes through autoantigen presentation. We propose that HLA-C*06:02 may predispose to psoriasis via this newly identified autoimmune pathway.
Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells
Authors: Gitte Olofsson, Manja Idorn, Ramona Schenker, Elfriede Nössner, Reno Debets, Bernhard Moser, Özcan Met, Per thor Straten
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts The human Vγ9Vδ2 T cells are a unique T cell type, and recent studies of the biology of Vγ9Vδ2 T cells emphasize the potential exploitation of these cells in immunotherapy of cancer. Vγ9Vδ2 T cells exhibit dual functionality in that they are both antigen presenting cells (
Risk factors for musculoskeletal injury in preprofessional dancers: a systematic review
Authors: Sarah J Kenny, Jackie L Whittaker, Carolyn A Emery
Journal: British Journal of Sports Medicine (2015)

Background Preprofessional dancers partake in rigorous training and have high injury prevalence. Attempts to identify risk factors for dance injuries have focused on a diversity of intrinsic and extrinsic factors. Objective To identify and evaluate the evidence examining risk factors for musculoskeletal injury in preprofessional ballet and modern dancers. Methods Fifteen electronic databases were systematically searched to October 2015. Studies selected met a priori inclusion criteria and investigated musculoskeletal injury risk factors in preprofessional (elite adolescent, student, young adult) ballet and modern dancers. Two reviewers independently assessed the quality and level of evidence using the Downs and Black (DB) criteria and a modified Oxford Centre of Evidence-Based Medicine 2009 model, respectively. Results Of 1364 potentially relevant studies, 47 were included and scored. Inconsistent injury definition and methodology precluded meta-analysis. The most common modifiable risk factors investigated were anthropometrics (ie, body mass index, adiposity), joint range of motion (ie, lower extremity), dance exposure (ie, years training, exposure hours) and age. The median DB score across studies was 8/33 (range 2–16). The majority of studies were classified as level 3 evidence and few considered risk factor inter-relationships. There is some level 2 evidence that previous injury and poor psychological coping skills are associated with increased injury risk. Conclusions Because of the lack of high-quality studies, consensus regarding risk factors for musculoskeletal injury in preprofessional dancers remains difficult. There is a need for injury definition consensus and high-quality prospective studies examining the multifactorial relationship between risk factors and injury in preprofessional dance.
Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Authors: K Y Shum, M G Kris, R J Gralla, M T Burke, L D Marks, R T Heelan
Journal: Journal of Clinical Oncology (1988)

10-ethyl-10-deaza-aminopterin (10-EDAM) is an analog of methotrexate that differs from its compound by modification of the N10 position and demonstrates greater preclinical antitumor activity and less toxicity. In this phase II trial, 20 patients with stage III or IV non-small-cell lung cancer (NSCLC) were administered 10-EDAM at a dose of 80 mg/m2 once weekly for 5 weeks. No patient had previously received chemotherapy. Nineteen of the 20 patients were adequately treated for response assessment. Six of 19 patients (32%) experienced a major objective response (exact 95% confidence limits, 15% to 55%). The median duration of response has not been reached and will exceed 13 months. Mucositis was the most common toxicity observed. Leukopenia was seen in only 10%, and 15% had platelet nadirs less than 100,000/microL. At the dosage and schedule used, 10-EDAM is an active agent in patients with NSCLC who are previously untreated with chemotherapy with a predicted response rate greater than or equal to 15% (P = .05). Because of its level of antitumor activity and the fact that 10-EDAM causes minimal myelosuppression, it is a suitable agent for further study in combination with other chemotherapeutic agents in this disease.